Oral solution containing astaxanthin and method for preparing the same

Abstract

This invention discloses an oral liquid containing astaxanthin and its preparation method, which is prepared from raw materials comprising the following weight percentages: 0.5%~2% astaxanthin burst beads, 8%~12% collagen peptides, 0.1%~0.3% sodium hyaluronate, 0.01%~2% elastin peptides, 0.01%~0.05% spermidine, 0.005%~0.02% ergothioneine, and 0.001%~0.01% pyrroloquinoline quinone. The astaxanthin burst beads are prepared using astaxanthin oil as the core material and sodium alginate and chitosan as the wall material. This invention, by using astaxanthin burst beads with higher stability and bioavailability in the oral liquid, combined with other ingredients, can improve the user's skin moisture content and elasticity index, reduce wrinkle depth, reduce skin yellowing, and better exert the effects of the oral liquid.

Description

Technical Field

[0001] This invention belongs to the field of food and skin care technology. Specifically, this invention relates to an oral liquid containing astaxanthin and its preparation method. Background Technology

[0002] Currently available oral beauty products generally contain ingredients such as collagen and hyaluronic acid, and are mostly formulated as tablets, capsules, or oral liquids. Astaxanthin, a naturally sourced carotenoid known to have antioxidant and anti-inflammatory effects, is also added to oral beauty products.

[0003] However, astaxanthin has poor water solubility and, as a potent antioxidant, poor photothermal sensitivity. Therefore, when added to oral liquids, it has poor stability and is easily degraded, resulting in low bioavailability and difficulty in exerting its effects. Summary of the Invention

[0004] Based on this, the purpose of the present invention is to improve the bioavailability of astaxanthin in oral liquid.

[0005] The specific technical solutions for achieving the above-mentioned objectives are as follows.

[0006] In a first aspect, the present invention provides an oral liquid containing astaxanthin, prepared from raw materials comprising the following weight percentages: 0.5%~2% astaxanthin burst beads, 8%~12% collagen peptides, 0.1%~0.3% sodium hyaluronate, 0.01%~2% elastin peptides, 0.01%~0.05% spermidine, 0.005%~0.02% ergothioneine, and 0.001%~0.01% pyrroloquinoline quinone; wherein the astaxanthin burst beads are prepared using astaxanthin oil as the core material and sodium alginate and chitosan as the wall material.

[0007] A second aspect of the present invention provides a method for preparing the above-mentioned oral liquid containing astaxanthin, comprising the following steps:

[0008] (1) Astaxanthin burst beads were prepared by the dripping method;

[0009] (2) In water at 35℃~45℃, add collagen peptides, sodium hyaluronate, elastin peptides, spermidine, ergothioneine and pyrroloquinoline quinone in sequence, stir until completely dissolved, and then adjust the pH to 4.0~4.5.

[0010] (3) Add astaxanthin popping beads, fill, sterilize, and you will get the product.

[0011] The inventors of this invention discovered that by using astaxanthin oil as the core material and sodium alginate and chitosan as the composite wall material, and by controlling the astaxanthin content in the astaxanthin oil, the weight ratio of sodium alginate and chitosan, and the weight ratio of the core material to the wall material, astaxanthin burst beads with a diameter of 1-3 mm can be prepared. The stability of these beads is greatly improved compared to that of astaxanthin itself. When added to oral liquids, astaxanthin can be prevented from being exposed to light and oxidation, and can be released in a controlled manner in the intestines, thereby greatly improving its stability in oral liquids and thus improving its bioavailability.

[0012] Based on this, the inventors of this invention added a certain amount of astaxanthin burst beads to the oral liquid, and added collagen peptides and elastin peptides to synergistically enhance skin elasticity, added sodium hyaluronate to improve skin moisturizing ability, and added spermidine, ergothioneine and pyrroloquinoline quinone to strengthen antioxidant and cellular energy metabolism, thus delaying skin aging. Under the combined effect of the above components, the oral liquid of this invention can improve the user's skin moisture content and elasticity index, reduce wrinkle depth, reduce skin yellowing, and better exert its effects.

[0013] In addition, adding astaxanthin to the oral liquid in the form of popping beads creates a pleasant taste when the beads burst in the mouth, thus improving user compliance. Detailed Implementation

[0014] To facilitate understanding of the present invention, a more complete description will be provided below. The present invention can be implemented in many different forms and is not limited to the embodiments described herein. Rather, these embodiments are provided to provide a thorough and complete understanding of the disclosure of the present invention.

[0015] Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. The terminology used in this specification is for the purpose of describing particular embodiments only and is not intended to limit the invention. The term "and / or" as used in this invention includes any and all combinations of one or more of the associated listed items.

[0016] Unless otherwise specified, all examples were conducted under standard experimental conditions or as recommended in the manufacturer's instructions. All raw materials used were commercially available and readily available.

[0017] In some embodiments of the present invention, an oral liquid containing astaxanthin is disclosed, which is prepared from raw materials comprising the following weight percentages: 0.5%~2% astaxanthin burst beads, 8%~12% collagen peptides, 0.1%~0.3% sodium hyaluronate, 0.01%~2% elastin peptides, 0.01%~0.05% spermidine, 0.005%~0.02% ergothioneine, and 0.001%~0.01% pyrroloquinoline quinone; wherein the astaxanthin burst beads are prepared with astaxanthin oil as the core material and sodium alginate and chitosan as the wall material.

[0018] In one embodiment, the astaxanthin content in the astaxanthin oil is 5% (w / v) to 10% (w / v).

[0019] In one embodiment, the astaxanthin content in the astaxanthin oil is 7.5% (w / v) to 8.5% (w / v).

[0020] In one embodiment, the weight ratio of sodium alginate to chitosan is 2-4:1.

[0021] In one embodiment, the weight ratio of sodium alginate to chitosan is 2.5 to 3.5:1.

[0022] In one embodiment, the weight ratio of the core material to the wall material is 5 to 8:1.

[0023] In one embodiment, the weight ratio of the core material to the wall material is 5.5 to 6.5:1.

[0024] In one embodiment, the oral liquid containing astaxanthin is prepared from raw materials comprising the following weight percentages: 1%~2% astaxanthin burst beads, 8%~10% collagen peptides, 0.2%~0.3% sodium hyaluronate, 1%~2% elastin peptides, 0.02%~0.04% spermidine, 0.01%~0.02% ergothioneine, and 0.003%~0.008% pyrroloquinoline quinone.

[0025] In one embodiment, the oral liquid containing astaxanthin is prepared from raw materials comprising the following weight percentages: 1%~1.4% astaxanthin burst beads, 8%~9% collagen peptides, 0.25%~0.3% sodium hyaluronate, 1.5%~2% elastin peptides, 0.02%~0.03% spermidine, 0.01%~0.02% ergothioneine, and 0.003%~0.006% pyrroloquinoline quinone.

[0026] In one embodiment, the oral liquid containing astaxanthin is prepared from raw materials comprising the following weight percentages: astaxanthin burst beads 1.1%~1.3%, collagen peptides 8%~8.5%, sodium hyaluronate 0.28%~0.3%, elastin peptides 1.8%~2%, spermidine 0.025%~0.03%, ergothioneine 0.01%~0.012%, and pyrroloquinoline quinone 0.004%~0.006%.

[0027] In one embodiment, the oral liquid containing astaxanthin further includes 0.01% to 0.05% of a flavoring agent and / or 0.08% to 0.12% of an acidity regulator.

[0028] In one embodiment, the flavoring agent is steviol glycoside and / or edible flavoring.

[0029] In one embodiment, the acidity regulator is citric acid monohydrate.

[0030] In one embodiment, the oral liquid containing astaxanthin is prepared from raw materials comprising the following weight percentages: 1.1%~1.3% astaxanthin burst beads, 8%~8.5% collagen peptides, 0.28%~0.3% sodium hyaluronate, 1.8%~2% elastin peptides, 0.025%~0.03% spermidine, 0.01%~0.012% ergothioneine, 0.004%~0.006% pyrroloquinoline quinone, 0.008%~0.012% steviol glycosides, 0.02%~0.04% edible flavoring, 0.08%~0.12% citric acid monohydrate, with the balance being water.

[0031] In other embodiments of the present invention, a method for preparing the above-mentioned oral liquid containing astaxanthin is disclosed, comprising the following steps:

[0032] (1) Astaxanthin burst beads were prepared by the dripping method;

[0033] (2) In water at 35℃~45℃, add collagen peptides, sodium hyaluronate, elastin peptides, spermidine, ergothioneine and pyrroloquinoline quinone in sequence, stir until completely dissolved, and then adjust the pH to 4.0~4.5.

[0034] (3) Add astaxanthin popping beads, fill, sterilize, and you will get the product.

[0035] In one embodiment, the astaxanthin burst beads in step (1) are prepared by a dripping method: astaxanthin oil is used as the core material and sodium alginate-chitosan composite solution is used as the wall material. The core material and wall material are dripped into calcium chloride solution by a dripping method, and after molding, they are washed and dried at low temperature.

[0036] In one embodiment, the concentration of the calcium chloride solution is 1% to 2%, the flow rate of the core material is 1 to 2 mL / min, the flow rate of the wall material is 0.2 to 0.4 mL / min, and the low temperature is ≤40°C.

[0037] The present invention will be described in detail below with reference to specific embodiments.

[0038] Example 1: An oral liquid containing astaxanthin

[0039] This embodiment provides an oral liquid containing astaxanthin, prepared from the following raw materials in weight percentages: 1.2% astaxanthin burst beads, 8% collagen peptides, 0.3% sodium hyaluronate, 2% elastin peptides, 0.03% spermidine, 0.01% ergothioneine, 0.005% pyrroloquinoline quinone (PQQ), 0.01% steviol glycosides, 0.1% citric acid monohydrate, 0.03% food flavoring, and the balance being purified water.

[0040] This embodiment also provides a method for preparing an oral liquid, including the following steps:

[0041] 1. Astaxanthin burst beads with a diameter of 1-3 mm were prepared by a double-layer encapsulation technology and a drop-in method. The core material of the burst beads was astaxanthin oil with an astaxanthin content of 8% (w / v), and the wall material of the burst beads was a sodium alginate-chitosan composite aqueous solution, wherein the concentration of sodium alginate was 1.5% (w / v) and the concentration of chitosan was 0.5% (w / v).

[0042] The weight ratio of core material to wall material is 6:1; a 1.5% calcium chloride solution is used as the coagulation bath, and the core material is added dropwise at a flow rate of 1.5 mL / min, while the wall material is added dropwise at a flow rate of 0.3 mL / min.

[0043] After molding, wash, vacuum dry at ≤40℃, and then sterilize at 110℃ for 30 min to obtain astaxanthin popping beads.

[0044] 2. Heat the purified water to 40℃, then add collagen peptides, sodium hyaluronate, and elastin peptides in sequence, and stir until completely dissolved;

[0045] 3. Add spermidine, ergothioneine, and PQQ, and continue stirring until dissolved;

[0046] 4. Add edible flavoring, steviol glycosides, and citric acid monohydrate, dissolve, and adjust the pH to 6.5;

[0047] 5. Add astaxanthin popping beads, fill into bottles, 50 mL each;

[0048] 6. Sterilize at 110℃ for 30 minutes to obtain the final product.

[0049] Example 2: An oral liquid containing astaxanthin

[0050] This embodiment provides an oral liquid containing astaxanthin, prepared from the following raw materials in weight percentages: 1.5% astaxanthin burst beads, 10% collagen peptides, 0.3% sodium hyaluronate, 1% elastin peptides, 0.03% spermidine, 0.01% ergothioneine, 0.005% pyrroloquinoline quinone (PQQ), 0.01% steviol glycosides, 0.1% citric acid monohydrate, 0.03% food flavoring, and the balance being purified water.

[0051] The preparation method of the oral liquid in this embodiment is the same as that in Embodiment 1.

[0052] Example 3: An oral liquid containing astaxanthin

[0053] This embodiment provides an oral liquid containing astaxanthin, prepared from the following raw materials in weight percentage: 1.0% astaxanthin burst beads, 10% collagen peptides, 0.2% sodium hyaluronate, 1% elastin peptides, 0.04% spermidine, 0.015% ergothioneine, 0.006% pyrroloquinoline quinone (PQQ), 0.01% steviol glycosides, 0.1% citric acid monohydrate, 0.03% food flavoring, and the balance being purified water.

[0054] The preparation method of the oral liquid in this embodiment is the same as that in Embodiment 1.

[0055] Comparative Example 1: An oral liquid containing astaxanthin

[0056] This comparative example provides an oral liquid containing astaxanthin, prepared from the following raw materials in weight percentages: astaxanthin 1.2%, collagen peptides 8%, sodium hyaluronate 0.3%, elastin peptides 2%, spermidine 0.03%, ergothioneine 0.01%, pyrroloquinoline quinone (PQQ) 0.005%, steviol glycosides 0.01%, citric acid monohydrate 0.1%, edible flavoring 0.03%, with the balance being purified water.

[0057] The preparation method of the oral liquid in this comparative example is the same as that in Example 1.

[0058] Comparative Example 2: An oral liquid containing astaxanthin

[0059] This comparative example provides an oral liquid containing astaxanthin, prepared from the following raw materials in weight percentages: 1.2% astaxanthin-containing algal microcapsule powder, 8% collagen peptides, 0.3% sodium hyaluronate, 2% elastin peptides, 0.03% spermidine, 0.01% ergothioneine, 0.005% pyrroloquinoline quinone (PQQ), 0.01% steviol glycosides, 0.1% citric acid monohydrate, 0.03% edible flavoring, and the balance being purified water.

[0060] Among them, the algal microcapsule powder contains 8 wt% astaxanthin. The algal microcapsule powder is made from Haematococcus pluvialis as the algal source using conventional microencapsulation technology.

[0061] The preparation method of the oral liquid in this comparative example is the same as that in Example 1.

[0062] Comparative Example 3: An oral liquid containing astaxanthin

[0063] This comparative example provides an oral liquid containing astaxanthin, prepared from the following raw materials in weight percentages: 2.5% astaxanthin burst beads, 8% collagen peptides, 0.3% sodium hyaluronate, 2% elastin peptides, 0.03% spermidine, 0.01% ergothioneine, 0.005% pyrroloquinoline quinone (PQQ), 0.01% steviol glycosides, 0.1% citric acid monohydrate, 0.03% edible flavoring, and the balance being purified water.

[0064] The preparation method of the astaxanthin burst beads in this comparative example is the same as that in Example 1, and the preparation method of the oral liquid is the same as that in Example 1.

[0065] Comparative Example 4: An oral liquid containing astaxanthin

[0066] This comparative example provides an oral liquid containing astaxanthin, prepared from the following raw materials in weight percentage: 1.2% astaxanthin burst beads, 10% collagen peptides, 0.3% sodium hyaluronate, 0.03% spermidine, 0.01% ergothioneine, 0.005% pyrroloquinoline quinone (PQQ), 0.01% steviol glycosides, 0.1% citric acid monohydrate, 0.03% food flavoring, and the balance being purified water.

[0067] The preparation method of the oral liquid in this comparative example is the same as that in Example 1.

[0068] Comparative Example 5: An oral liquid containing astaxanthin

[0069] This comparative example provides an oral liquid containing astaxanthin, prepared from the following raw materials in weight percentage: 1.2% astaxanthin burst beads, 8% collagen peptides, 0.3% sodium hyaluronate, 2% elastin peptides, 0.03% spermidine, 0.015% ergothioneine, 0.01% steviol glycosides, 0.1% citric acid monohydrate, 0.03% edible flavoring, and the balance being purified water.

[0070] The preparation method of the oral liquid in this comparative example is the same as that in Example 1.

[0071] Experiment Example 1: Efficacy Test of Oral Liquid

[0072] Thirty healthy subjects (aged 25-45 years, male-female ratio 1:5) were selected and took 50 mL of the astaxanthin oral solution of Example 1 and Comparative Examples 4-5 of this invention daily for 28 consecutive days.

[0073] Skin-related indicators were measured using a skin analyzer before and after the experiment, and the results are shown in Table 1. Results are expressed as mean ± standard deviation.

[0074] Table 1

[0075]

[0076] As shown in Table 1, after 28 days of continuous use of the astaxanthin oral solution of Example 1, the skin moisture content and skin elasticity index of the users increased by more than 10%, while the wrinkle depth and skin yellowness value decreased by more than 4%. The astaxanthin oral solutions of Comparative Examples 4 and 5 were significantly less effective than the astaxanthin oral solution of Example 1 in improving skin-related indicators.

[0077] Meanwhile, the satisfaction of the subjects was statistically analyzed through questionnaires. The overall satisfaction of the subjects with the taste, ease of use and effects of the oral liquids in Example 1 and Comparative Examples 4-5 was 100%, and no adverse reactions were reported.

[0078] Example 2: Stability and bioavailability performance testing of oral solutions

[0079] The following performance tests were conducted on the oral liquids of Example 1 and Comparative Examples 1-3 in this experiment:

[0080] 1. Stability test

[0081] Take oral liquid samples from Example 1 and Comparative Examples 1-3 (n=3), place them in a light incubator with a light intensity of 4500 lx ± 500 lx, and place them continuously for 14 days. Take samples on day 0 and day 14, and determine the astaxanthin content by high performance liquid chromatography (HPLC) (refer to GB / T 31520-2015) and calculate the astaxanthin retention rate.

[0082] Take oral liquid samples from Example 1 and Comparative Examples 1-3 (n=3), place them at a constant temperature of 40℃ for 14 days, and take samples on day 0 and day 14 respectively. Determine the astaxanthin content by high performance liquid chromatography (HPLC) (refer to GB / T 31520-2015) and calculate the astaxanthin retention rate.

[0083] Astaxanthin retention rate (%) = Astaxanthin content at 14 days / Astaxanthin content at 0 days × 100%.

[0084] The astaxanthin retention rates of each group of oral liquid samples after being placed under light and heat conditions for 14 days are shown in Table 2.

[0085] Table 2

[0086]

[0087] The results in Table 2 show that, compared with the oral liquids of Comparative Examples 1-3, the oral liquid of Example 1 has a significantly higher astaxanthin retention rate and significantly better stability under light and high temperature conditions.

[0088] 2. In vitro simulated gastric juice degradation test

[0089] A simulated gastric juice (pH 1.2) was prepared according to the General Chapter of Part IV of the 2020 edition of the Chinese Pharmacopoeia. Equal volumes of the oral solutions from Examples 1 and Comparative Examples 1-3 (n=3) were added to the simulated gastric juice and incubated at 37°C for 2 hours. The astaxanthin content was determined by high-performance liquid chromatography (HPLC) (referencing GB / T 31520-2015), and the degradation rate after 2 hours was calculated. Degradation rate (%) = (initial astaxanthin content - astaxanthin content after 2 hours) / initial astaxanthin content × 100%.

[0090] The degradation rate of astaxanthin in each group of oral liquid samples after 2 hours is shown in Table 3.

[0091] Table 3

[0092]

[0093] The results in Table 3 show that, compared with the oral liquids of Comparative Examples 1-3, the oral liquid of Example 1 has a significantly lower astaxanthin degradation rate and stronger anti-degradation ability in simulated gastric juice in vitro.

[0094] 3. In vitro bioavailability test

[0095] In vitro permeability tests were conducted using a Caco-2 cell monolayer model to determine the apparent permeability coefficient (Papp) of astaxanthin in oral liquid samples (n=3) of Example 1 and Comparative Examples 1-3. The relative bioavailability was calculated with Example 1 as a reference.

[0096] Relative bioavailability (%) = Sample Papp / Example 1 Papp × 100%.

[0097] The relative bioavailability results of the oral liquid samples of Comparative Examples 1 to 3 are shown in Table 4.

[0098] Table 4

[0099]

[0100] The results in Table 4 show that the apparent permeability coefficients of astaxanthin in the oral liquids of Comparative Examples 1-3 are significantly lower than those of the oral liquid of Example 1. Therefore, the relative bioavailability of the oral liquid containing astaxanthin capsules of the present invention is significantly higher.

[0101] The technical features of the above embodiments can be combined in any way. For the sake of brevity, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0102] The embodiments described above are merely illustrative of several implementations of the present invention, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the invention patent. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these all fall within the protection scope of the present invention. Therefore, the protection scope of this invention patent should be determined by the appended claims.

Claims

1. An oral liquid containing astaxanthin, characterized in that, It is prepared from raw materials comprising the following weight percentages: 0.5%~2% astaxanthin burst beads, 8%~12% collagen peptides, 0.1%~0.3% sodium hyaluronate, 0.01%~2% elastin peptides, 0.01%~0.05% spermidine, 0.005%~0.02% ergothioneine, and 0.001%~0.01% pyrroloquinoline quinone; the astaxanthin burst beads are prepared using astaxanthin oil as the core material and sodium alginate and chitosan as the wall material.

2. The oral liquid containing astaxanthin according to claim 1, characterized in that, The astaxanthin content in the astaxanthin oil is 5% to 10%, preferably 7.5% to 8.5%; And / or, the weight ratio of sodium alginate to chitosan is 2~4:1, preferably 2.5~3.5:1; And / or, the weight ratio of the core material to the wall material is 5~8:1, preferably 5.5~6.5:

1.

3. The oral liquid containing astaxanthin according to claim 1, characterized in that, It is prepared from the following raw materials in weight percentage: astaxanthin burst beads 1%~2%, collagen peptides 8%~10%, sodium hyaluronate 0.2%~0.3%, elastin peptides 1%~2%, spermidine 0.02%~0.04%, ergothionein 0.01%~0.02%, and pyrroloquinoline quinone 0.003%~0.008%.

4. The oral liquid containing astaxanthin according to claim 3, characterized in that, It is prepared from raw materials comprising the following weight percentages: astaxanthin burst beads 1%~1.4%, collagen peptides 8%~9%, sodium hyaluronate 0.25%~0.3%, elastin peptides 1.5%~2%, spermidine 0.02%~0.03%, ergothioneine 0.01%~0.02%, and pyrroloquinoline quinone 0.003%~0.006%.

5. The oral liquid containing astaxanthin according to claim 4, characterized in that, It is prepared from raw materials comprising the following weight percentages: astaxanthin burst beads 1.1%~1.3%, collagen peptides 8%~8.5%, sodium hyaluronate 0.28%~0.3%, elastin peptides 1.8%~2%, spermidine 0.025%~0.03%, ergothioneine 0.01%~0.012%, and pyrroloquinoline quinone 0.004%~0.006%.

6. The oral liquid containing astaxanthin according to any one of claims 1 to 5, characterized in that, It also includes 0.01% to 0.05% of flavoring agents and / or 0.08% to 0.12% of acidity regulators.

7. The oral liquid containing astaxanthin according to claim 6, characterized in that, The flavoring agent is steviol glycosides and / or edible flavoring; the acidity regulator is citric acid monohydrate.

8. The oral liquid containing astaxanthin according to claim 1, characterized in that, It is prepared from the following raw materials in weight percentage: astaxanthin burst beads 1.1%~1.3%, collagen peptides 8%~8.5%, sodium hyaluronate 0.28%~0.3%, elastin peptides 1.8%~2%, spermidine 0.025%~0.03%, ergothioneine 0.01%~0.012%, pyrroloquinoline quinone 0.004%~0.006%, steviol glycosides 0.008%~0.012%, edible flavoring 0.02%~0.04%, citric acid monohydrate 0.08%~0.12%, and the balance being water.

9. The method for preparing the oral liquid containing astaxanthin according to any one of claims 1 to 8, characterized in that, Includes the following steps: (1) Astaxanthin burst beads were prepared by the dripping method; (2) In water at 35℃~45℃, add collagen peptides, sodium hyaluronate, elastin peptides, spermidine, ergothioneine and pyrroloquinoline quinone in sequence, stir until completely dissolved, and then adjust the pH to 4.0~4.

5. (3) Add astaxanthin popping beads, fill, sterilize, and you will get the product.

10. The method for preparing an oral liquid containing astaxanthin according to claim 9, characterized in that, Step (1) is as follows: Astaxanthin oil is used as the core material and sodium alginate-chitosan composite solution is used as the wall material. The core material and wall material are dripped into the calcium chloride solution by the dripping method. After molding, the solution is washed and dried at low temperature.

Images